Navigation

Clinical Research

Our team of highly trained specialists is dedicated to offering patients the most advanced treatment available for their condition through clinical research.

Recurrent and Newly Diagnosed Glioblastoma – Now Enrolling

Recurrent and Newly Diagnosed Glioblastoma: BeiGene BGB-290 Study

This study is to evaluate the safety, efficacy and clinical activity of BGB-290 in combination with radiation therapy (RT) and/or temozolomide (TMZ) in subjects with newly diagnosed or recurrent/refractory glioblastoma.

Study Enrollment

If you, your family member or loved one is interested in learning more about participating in this study, please contact the BeiGene Study Coordinator at 520-320-2157.